ApoM-Fc fusion proteins, complexes thereof with sphingosine 1-phosphate (S1P), and methods for treating vascular and non-vascular diseases
AssigneeChildren's Medical Center Corporation
InventorsTimothy T. Hla, Steven L. Swendeman, Annarita DiLorenzo, Teresa Sanchez
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to an engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperone derived from an Apolipoprotein M (ApoM)-Fc fusion protein having an extended half life in vivo. The disclosed ApoM-Fc fusion protein provides a safe, efficient and effective means of delivering S1P to endothelial cells and to all tissues of the body.
Claims17
A fusion protein comprising an Apolipoprotein M (ApoM) polypeptide fused to a fragment crystallizable (Fc) region of an antibody, wherein the ApoM polypeptide comprises amino acids 21-188 of SEQ ID NO:
- 9 and does not comprise amino acids 1-20 of SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.